PRRT2 and Myocardial fibrosis: Although PKC activation was recently shown to have antifibrotic effect in cardiac fibroblasts suggesting potential strategy to inhibit myocardial fibrosis (Karhu et al., 2020a), the pro-hypertrophic role of PKC agonists should be considered.